Assessment superseded
SEN-SURVIVORS: An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 24, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- No efficacy data are presented—this is a protocol or interim report, not a results paper. Open-label design without placebo control means results would be vulnerable to bias and placebo effects. The study is explicitly a pilot generating preliminary evidence; it cannot establish efficacy for the senolytic interventions or that they improve frailty in this population.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 5 months
- Population
- Adult survivors of childhood cancer
- Primary outcome
- Change in walking speed and senescent cell abundance in blood (p16^INK4A) at 60 days, with extended follow-up at 150 days
- Effect size
- —
- Significance
- Not reported
- Journal
- St. Jude Children's Research Hospital
- Published
- Sep 30, 2026
Sources
Primary source
- St. Jude Children's Research Hospital ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This is a first-in survivor pilot study with the goal of establishing preliminary evidence of efficacy, safety, and tolerability of two senolytic regimens to reduce markers of cellular senescence (primary outcome: p16^INK4a) and improve frailty (primary outcome: walking speed) in adult survivors of childhood cancer.
Primary endpoints of this trial will be change in walking speed and senescent cell abundance in blood (p16^INK4A) determined at baseline and again at 60 days, within an individual arm. Extended follow up at 150 days will assess the permanence of change after completion of the trial.
The primary aim of this proposal is to test the efficacy of two, short duration senolytic regimens: 1) combination of Dasatinib plus Quercetin and 2) Fisetin alone, to improve walking speed and decrease senescent cell abundance in blood (p16^INKA)
Source versions
Assessment history
9/30/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.